ALLOGENE THERAPEUTICS, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
R&D
$150M
D&A
$12M
Operating Income
$-209M
EBITDA
$-197M
Interest Expense
$1M
Other Income/Expense
$20M
Pretax Income
$-191M
Tax Provision
$0
Net Income
$-191M
Operating Margin
-1241813.6%
Net Margin
-1170863.6%
Effective Tax Rate
0.0%
Deferred Tax Liabilities
—
DTA Valuation Allowance
$502M
Tax Credit Carryforwards
$38M
NOL Carryforwards
$315M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
Operating Lease Cost
$10M
Revenue YoY Variation
-100.0%
Income YoY Variation
23.4%